Literature DB >> 23720698

Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Volker Neumann1, Stefan Löseke, Dennis Nowak, Felix J F Herth, Andrea Tannapfel.   

Abstract

BACKGROUND: The incidence of malignant mesothelioma in Germany is about 20 cases per million persons per year. Its association with asbestos exposure, usually occupational, has been unequivocally demonstrated. Even though the industrial use of asbestos was forbidden many years ago, new cases of mesothelioma continue to appear because of the long latency of the disease (median, 50 years). Its diagnosis and treatment still present a major challenge for ambulatory and in-hospital care and will do so for years to come.
METHODS: This article is based on a selective review of the literature, along with data from the German Mesothelioma Register.
RESULTS: 1397 people died of mesothelioma in Germany in 2010. A plateau in the incidence of the disease is predicted between 2015 and 2030. Most mesotheliomas arise from the pleura. The histological subtype and the Karnofsky score are the main prognostic factors. Only limited data are now available to guide treatment with a combination of the available methods (chemotherapy, surgery, radiotherapy). The prognosis is still poor, with a median survival time of only 12 months. Symptom control and the preservation of the patient's quality of life are the main aspects of care for patients with mesothelioma.
CONCLUSION: The incidence of mesothelioma is not expected to drop in the next few years. The available treatments are chemotherapy, surgery, and radiotherapy. Specialized treatment centers now increasingly provide multimodal therapy for treatment of mesothelioma.

Entities:  

Mesh:

Year:  2013        PMID: 23720698      PMCID: PMC3659962          DOI: 10.3238/arztebl.2013.0319

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  75 in total

1.  Asbestos is still with us: Repeat call for a universal ban.

Authors:  Collegium Ramazzini
Journal:  Am J Ind Med       Date:  2010-10-18       Impact factor: 2.214

2.  Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.

Authors:  Servet Bölükbas; Christian Manegold; Michael Eberlein; Thomas Bergmann; Annette Fisseler-Eckhoff; Joachim Schirren
Journal:  Lung Cancer       Date:  2009-09-17       Impact factor: 5.705

Review 3.  Surgical therapy of mesothelioma.

Authors:  David Rice
Journal:  Recent Results Cancer Res       Date:  2011

Review 4.  Imaging of mesothelioma.

Authors:  Ritu R Gill
Journal:  Recent Results Cancer Res       Date:  2011

5.  [Diagnostics and expert opinion of asbestos-induced occupational diseases].

Authors:  X Baur; M Clasen; A Fisseler-Eckhoff; M Heger; K G Hering; K Hofmann-Preiss; D Köhler; A Kranig; T Kraus; S Letzel; V Neumann; A Tannapfel; J Schneider; H Sitter; H Teschler; T Voshaar; A Weber
Journal:  Pneumologie       Date:  2011-01-18

6.  Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

Authors:  P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

7.  Tumor type influences the effectiveness of pleurodesis in malignant effusions.

Authors:  Silvia Bielsa; Paula Hernández; Francisco Rodriguez-Panadero; Teresa Taberner; Antonieta Salud; José M Porcel
Journal:  Lung       Date:  2011-02-18       Impact factor: 2.584

Review 8.  Epidemiology of mesothelioma and historical background.

Authors:  J E Craighead
Journal:  Recent Results Cancer Res       Date:  2011

Review 9.  Pathohistological diagnosis and differential diagnosis.

Authors:  Iris Tischoff; Matthias Neid; Volker Neumann; Andrea Tannapfel
Journal:  Recent Results Cancer Res       Date:  2011

Review 10.  Mesothelioma and analysis of tissue fiber content.

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Recent Results Cancer Res       Date:  2011
View more
  29 in total

1.  Progress means change: reflections on two articles about pleural disease.

Authors:  Tobias Welte
Journal:  Dtsch Arztebl Int       Date:  2013-05       Impact factor: 5.594

2.  In reply.

Authors:  Volker Neumann; Stefan Löseke; Dennis Nowak; Felix J F Herth
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

3.  Surgical therapeutic options.

Authors:  Servet Bölükbas; Joachim Schirren
Journal:  Dtsch Arztebl Int       Date:  2013-09       Impact factor: 5.594

4.  Process analysis of carcinogenesis: concept derivation of the tissue function "preservation of a homogeneous gene expression".

Authors:  Thomas Löser
Journal:  Theory Biosci       Date:  2017-10-30       Impact factor: 1.919

5.  Advanced malignant mesothelioma mimicking acute contained thoracic aortic rupture.

Authors:  Nicolas J Mouawad; Vincent C Daniel; Jean E Starr
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-10-30

Review 6.  Role of microRNAs in malignant mesothelioma.

Authors:  A Truini; S Coco; A Alama; C Genova; C Sini; M G Dal Bello; G Barletta; E Rijavec; G Burrafato; F Boccardo; F Grossi
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

Review 7.  [The German Mesothelioma Register : Current pathological diagnostics and services].

Authors:  I S Feder; M Jülich; A Tannapfel; I Tischoff
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

Review 8.  Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.

Authors:  Halil Yildiz; Stoian Ioana Andreea; Delphine Hoton; Jean Cyr Yombi
Journal:  BMJ Case Rep       Date:  2016-12-19

Review 9.  Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.

Authors:  Weiquan Zhang; Xinshu Wu; Licun Wu; Weidong Zhang; Xiaogang Zhao
Journal:  Ann Transl Med       Date:  2015-08

10.  [Mesothelioma].

Authors:  I Tischoff; A Tannapfel
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.